HWAM
AERI

Hennion & Walsh Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History

Hennion & Walsh Asset Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,394
Closed -$364K – 764
2021
Q1 		$364K Buy
+20,394
New +$352K 0.02% 554

Other funds holding AERI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Hennion & Walsh Asset Management's AERI Position: Q2 2021 in Review

Hennion & Walsh Asset Management sold out of Aerie Pharmaceuticals (AERI) in Q2 2021, closing a stake of 20,394 shares — an estimated $364K sold.

Hennion & Walsh Asset Management first reported a position in AERI in Q1 2021 and held it in 1 quarter. The position peaked at $364K in Q1 2021. 142 funds tracked by Wall St. Rank hold AERI as of Q2 2021.

  • Hennion & Walsh Asset Management reported no remaining Aerie Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 20,394 Aerie Pharmaceuticals shares in Q2 2021, an estimated $364K.
  • Hennion & Walsh Asset Management first reported a position in Aerie Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Hennion & Walsh Asset Management's Aerie Pharmaceuticals position peaked at $364K in Q1 2021.
  • 142 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2021.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.